Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons

Blood

Volumn 99, Issue 10, 2002, Pages 3623-3628

  Wu, Dongmei ^a,b   Vanhoorelbeke, Karen ^a,b   Cauwenberghs, Nancy ^a,b   Meiring, Muriel ^a,b   Depraetere, Hilde ^a,b   Kotze, Harry F ^a,b   Deckmyn, Hans ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF THE FREE STATE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; COLLAGEN; GLYCOPROTEIN IB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 82D6A3; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY THROMBOSIS; ARTICLE; BABOON; BINDING AFFINITY; BLEEDING TIME; CONTROLLED STUDY; DRUG EFFICACY; DRUG INFUSION; FEMALE; FEMORAL ARTERY FLOW; HEMOSTASIS; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SHEAR STRESS; THROMBOGENESIS; THROMBOSIS;

EID: 0037093219     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.10.3623     Document Type: Article

References (22)

1. The hemostatic plug
2. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor
3. Platelet-collagen interactions
4. A new platelet receptor specific to type III collagen. Type III collagen-binding protein
5. GPIIb-IIIa: The responsive integrin
6. Identification of aspartic acid 514 through glutamic acid 542 as a glyco-protein lb-IX complex receptor recognition sequence in von Willebrand factor. Mechanism of modulation of von Willebrand factor by ristocetin and botrocetin
7. A3 domain is essential for interaction of von Willebrand factor with collagen type III
8. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor
9. Echicetin: A snake venom protein that inhibits binding of von Willebrand factor and alboaggregins to platelet glycoprotein lb
10. Anti-thrombotic effect of crotalin, a platelet membrane glycoprotein lb antagonist from venom of Crotalus atrox
11. Reduction in thrombus formation by PG-1 F(ab′)2, an anti-guinea pig platelet glycoprotein lb monoclonal antibody
12. Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein lb binding domain
13. Antithrombotic effect of platelet glycoprotein lb-blocking monoclonal antibody Fab fragments in nonhuman primates
14. Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates
15. Antagonism of vWF inhibits both injury induced arterial and venous thrombosis in the hamster
16. Aurintricarboxylic acid reduces platelet deposition in stenosed and endothelially injured rabbit carotid arteries more effectively than other antiplatelet interventions
17. Von Willebrand factor binds to native collagen VI primarily via its A1 domain
18. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis
19. Inhibition of platelet glycoprotein lb, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons
20. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor
21. Cyclic flow variations in a conscious dog model of coronary artery stenosis and endothelial injury correlate with acute ischemic heart disease syndromes in humans
22. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen